ArticleScientific reports2026
Comprehensive 16s rRNA sequencing and metabolomics to investigate the effect of anticancer bioactive peptides combined with oxaliplatin on gastric cancer.
Article in Scientific reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
Abstract
The occurrence and development of gastric cancer are closely related to the gut microbiota. Previous studies have found that the combination of anticancer bioactive peptides (ACBP) and oxaliplatin (OXA) has a significant therapeutic effect on gastric cancer. However, the impact of ACBP-OXA on the gut microbiota remains unclear. In this study, we established a nude mouse model of ACBP-OXA for gastric cancer. Here, we set out to investigate the diversity of gut microbiota and fecal metabolomics and the correlation between gut microbiota and metabolites. We demonstrated that ACBP-OXA has a significant regulatory effect on the gut microbiota. 16s rRNA research has found that the relative abundance of Firmicutes and Bacteroidetes in the phylum changed significantly after the ACBP-OXA group. Specifically, the relative abundance of Firmicutes decreased, while Bacteroidetes increased. In the genus, the relative abundance of the Lachnospiraceae NK4AB6 group decreased in the ACBP-OXA group, while the relative abundance of Odpribacter and Bacteroides increased. The relative abundance of Lactobacillus increased in the ACBP group, while the relative abundance of Staphylococcus decreased in the ACBP-OXA and OXA groups. Gene Ontology and Kyoto Encyclopedia of Genes and Genomes (KEGG) studies have found that the ACBP-OXA mechanism is related to metabolism and immunity. Furthermore, we found that differential metabolites were associated with Neolignans and lipids that are involved in tyrosine metabolism, unsaturated fatty acid biosynthesis, and Phenylalanine metabolism, α- Biological processes. Combining metabolomics with 16S rRNA sequencing, researchers discovered that amino acid-related metabolites are associated with bacterial genera such as Jetgalilicus, Staphylococcus, and Proteiniphilum. Collectively, the combination therapy of ACBP-OXA and ACBP alone may improve and restore the gut microbiota of nude mice with gastric cancer by altering the distribution, diversity, and structure of the gut microbiota, which may be the key to inhibiting the occurrence and development of gastric cancer. This study provides a new direction for further research on the application of ACBP-OXA in treating gastric cancer.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.